Sabine Kayser

Mannheim, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 65 publications

Quizartinib: FLT3-ITD or not, does it matter?

Quizartinib: FLT3-ITD or not, does it matter?

Journal: Haematologica
Published: June 05, 2026

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.

Journal: British journal of haematology
Published: March 04, 2026

All patients with AML and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? - the PRO.

All patients with AML and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? - the PRO.

Journal: Haematologica
Published: December 30, 2025

Hemodynamic effects of red blood cell transfusion in patients with hemato-oncologic diseases.

Hemodynamic effects of red blood cell transfusion in patients with hemato-oncologic diseases.

Journal: Frontiers in medicine
Published: September 23, 2025

Impact of Preanalytical Sample Preparation on the Recovery Rate of Cryopreserved Allogeneic Hematopoietic Stem Cells.

Impact of Preanalytical Sample Preparation on the Recovery Rate of Cryopreserved Allogeneic Hematopoietic Stem Cells.

Journal: European journal of haematology
Published: August 28, 2025

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

Journal: American journal of hematology
Published: August 18, 2025

Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMSlike tyrosine kinase 3 internal tandem duplication.

Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMSlike tyrosine kinase 3 internal tandem duplication.

Journal: Haematologica
Published: May 31, 2025

Changes in central and peripheral hemodynamic parameters during blood donation.

Changes in central and peripheral hemodynamic parameters during blood donation.

Journal: Frontiers in cardiovascular medicine
Published: May 30, 2025

Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.

Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 16, 2024

Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/ hypomethylating agents.

Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/ hypomethylating agents.

Journal: Haematologica
Published: June 09, 2024

Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations.

Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations.

Journal: Cancers
Published: February 15, 2024

Antibody-drug conjugates in acute myeloid leukaemia: more research needed.

Antibody-drug conjugates in acute myeloid leukaemia: more research needed.

Journal: The Lancet. Oncology
Published: December 21, 2023
Showing 1-12 of 65

Last Updated: 09/26/2026